Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection
- Submitting institution
-
King's College London
- Unit of assessment
- 12 - Engineering
- Output identifier
- 97620335
- Type
- D - Journal article
- DOI
-
10.1111/ajt.14185
- Title of journal
- American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
- Article number
- -
- First page
- 931
- Volume
- 17
- Issue
- 4
- ISSN
- 1600-6135
- Open access status
- Compliant
- Month of publication
- December
- Year of publication
- 2016
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- Yes
- Number of additional authors
-
11
- Research group(s)
-
-
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- There is a worldwide, increasing shortage of transplant donor organs, making it paramount to increase transplant success and transplant longevity. Chimeric antigen receptors (CARs) are artificial engineered molecules that, as part of a new cell therapy, suppress rejection of transplanted organs and increase their half-lives. Employing cell and molecular engineering, we pioneered the concept of CARs in organ transplantation using human skin transplant animal-models. It underpinned the formation of Quell Therapeutics, in partnership between King’s College London, University College London and Hannover Medical School (contact@quell-tx.com), and led to a successful UKRI Higher Education Innovation Fund (Connecting Capability Fund application, CCF08-3645).
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -